Business Daily Media

Business Marketing

.

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

  • Written by ACN Newswire - Press Releases

image

TOKYO, Oct 23, 2019 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) has announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease (AD). The Phase 3 EMERGE Study met its primary

Read more //?#

Popular

Investment in creativity is key for businesses looking to better the bottom line

New data released today at Sydney’s SXSW by creative transformation company, WPP shines a spotlight on the importance of a brand’s continued ability to invest in creativity. Releasing the WPP Creative Capital Index, the tool a...

The activity gifting platform driving small business sales

With the rising cost of living and soaring inflation, many parents are under pressure to cut their children’s extracurricular and sporting activities out of their budgets. The current economic conditions have rapidly reduced c...

The Future of Privacy and Data Protection in an Increasingly Digital World

Our daily lives are now closely connected by the use of data in a time of fast technological advancements and a highly interconnected digital world. Gathering and using data have become basic parts of modern life, from how we ...

Virtual Office
Tomorrow Business Growth